Loading stock data…
EHC
$104.17+3.06 (+3.03%)
After Hours$104.19+0.02 (+0.02%)· Last close Jun 9
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Encompass Health Corporation in the Healthcare sector is trading at $104.17. Wall Street consensus targets $140.50 (12 analysts), implying a +34.9% move over the next 12 months. The stock is currently 19% below its 52-week high of $127.99, remaining 5.3% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +34.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$104.17
Potential Downside
0%
Whystock Fair Value$104.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$140.50+34.9%
Range$125.00 – $152.00
Fundamentals
Encompass Health Corporation operates inpatient rehabilitation hospitals in the United States and Puerto Rico. The company offers specialized rehabilitative treatment, using technology and therapy, on an inpatient basis for patients recovering from a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.71%
ROE
Elite ROE. Management converts capital into profit efficiently.
24.16%
Volume
Today's trading volume
571,165
Recent News
Assessing Encompass Health (EHC) Valuation After Recent Share Price Weakness
Stock performance snapshot Encompass Health (EHC) has drawn attention after a period of weaker share performance, with the stock down 1.1% on the day and declining over the past week, month, past 3 months, and year. See our latest analysis for Encompass Health. Recent share price returns show momentum fading, with the stock down over the past month and year to date, while longer term total shareholder returns over three and five years remain materially positive. If this kind of mixed...
3 Profitable Stocks That Fall Short
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
1 Mid-Cap Stock for Long-Term Investors and 2 We Brush Off
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Encompass Health to Expand WV Footprint With 36-Bed Bridgeport Unit
EHC is expanding its rehabilitation network with a new 36-bed hospital in West Virginia.
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.2% return has trailed the S&P 500 by 8.6 percentage points.